Caris Life Sciences, Inc. (CAI) Key Metrics
CAI valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $8.64B
- Enterprise value
- $8.60B
- P/E (TTM)
- 18.1
- Forward P/E
- 43.3
- PEG ratio
- —
- Price / sales
- 8.7
- Price / book
- 15.1
- EV / EBITDA
- 49.8
- Dividend yield
- —
- Beta
- —
CAI key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCAI returns How much profit the business earns on the capital it uses.
CAI per-share figures Results divided by the shares outstanding at year-end.
CAI financial health Debt, liquidity and how easily interest is covered.
CAI efficiency & capital use Working capital cycle and where the cash goes.
CAI valuation history
CAI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CAI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CAI cash returned to shareholders
CAI price vs earnings per share
CAI key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $7.82B | — | — | — | — | — | — | — | — | — |
| Enterprise value | $7.40B | — | — | — | — | — | — | — | — | — |
| Price / sales | 9.6 | — | — | — | — | — | — | — | — | — |
| Price / book | 13.5 | — | — | — | — | — | — | — | — | — |
| Price / free cash flow | 116.9 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 94.1 | — | — | — | — | — | — | — | — | — |
| EV / sales | 9.1 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 650.3 | — | — | — | — | — | — | — | — | — |
| EV / free cash flow | 110.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −6.9% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | 0.9% | — | — | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $26.98 | — | — | — | — | — | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $2.80 | $1.62 | $1.20 | $1.01 | — | — | — | — | — | — |
| Earnings per share | −$1.86 | −$1.11 | −$1.34 | −$1.26 | — | — | — | — | — | — |
| Operating cash flow per share | $0.29 | −$0.96 | −$1.08 | −$1.12 | — | — | — | — | — | — |
| Free cash flow per share | $0.23 | −$1.00 | −$1.17 | −$1.29 | — | — | — | — | — | — |
| Cash per share | $2.76 | $0.26 | $0.48 | $1.61 | — | — | — | — | — | — |
| Book value per share | $1.99 | −$9.81 | −$8.42 | −$6.68 | — | — | — | — | — | — |
| Tangible book value per share | $1.92 | −$9.89 | −$8.50 | −$6.76 | — | — | — | — | — | — |
| Capex per share | $0.06 | $0.03 | $0.09 | $0.17 | — | — | — | — | — | — |
| Debt per share | $1.31 | $1.67 | $0.85 | $1.06 | — | — | — | — | — | — |
| Shares outstanding | 289.9M | 254.7M | 254.7M | 254.8M | — | — | — | — | — | — |
| Change in shares outstanding | +13.8% | 0.0% | −0.0% | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | 4.0% | 4.4% | 12.4% | 14.1% | 1.3% | 5.9% |
| Return on invested capital (ROIC) | — | — | — | — | 5.2% | 4.4% | 5.8% | 5.2% | 2.2% | 3.4% |
| Return on assets (ROA) | −73.2% | −74.5% | −60.4% | −19.3% | 1.0% | 1.0% | 2.9% | 3.2% | 0.3% | 1.4% |
| Return on tangible assets | −48.6% | −86.9% | −86.8% | −46.0% | 1.1% | 1.1% | 2.6% | 3.0% | 0.3% | 1.4% |
| Free cash flow margin | 8.2% | −61.5% | −97.5% | −126.9% | 19.6% | −15.6% | −146.5% | −99.6% | −41.4% | −96.9% |
| Income quality (OCF / net income) | — | — | — | — | 9.99 | 8.19 | 2.29 | 2.15 | 21.55 | 5.49 |
| Financial health | ||||||||||
| Total debt | $379.0M | $424.3M | $217.3M | $270.9M | $1.75B | $2.10B | $2.16B | $1.70B | $1.48B | $1.43B |
| Cash & short-term investments | $800.1M | $66.2M | $121.6M | $409.6M | $132.5M | $46.5M | $121.3M | $65.5M | $66.1M | $73.7M |
| Net debt | −$421.1M | $358.1M | $95.7M | −$138.8M | $1.61B | $2.05B | $2.04B | $1.64B | $1.41B | $1.36B |
| Debt / equity | 0.66 | — | — | — | 2.49 | 3.03 | 3.08 | 3.02 | 3.23 | 3.11 |
| Debt / assets | 0.34 | 1.23 | 0.53 | 0.38 | 0.67 | 0.72 | 0.72 | 0.70 | 0.72 | 0.72 |
| Net debt / EBITDA | −37.00 | — | — | — | 6.34 | 8.26 | 7.19 | 7.33 | 8.85 | 7.49 |
| Current ratio | 7.85 | 1.30 | 2.55 | 3.77 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Quick ratio | 7.35 | 1.06 | 2.04 | 3.43 | 0.67 | 1.74 | 0.52 | 0.54 | 0.82 | 0.66 |
| Interest coverage | 0.8 | -5.1 | -10.1 | -11.8 | 2.3 | 1.6 | 1.9 | 2.0 | 1.5 | 1.9 |
| Working capital | $870.7M | $50.3M | $147.5M | $379.1M | −$105.6M | $211.7M | −$205.5M | −$119.6M | −$28.9M | −$73.8M |
| Invested capital | $156.2M | −$2.14B | −$2.05B | −$1.84B | $2.32B | $2.74B | $2.74B | $2.20B | $1.87B | $1.82B |
| Tangible asset value | $558.0M | −$2.52B | −$2.16B | −$1.72B | $702.2M | $673.3M | $679.6M | $540.3M | $432.0M | $457.1M |
| Net current asset value | $449.4M | −$2.63B | −$2.32B | −$1.90B | −$1.70B | −$1.71B | −$2.09B | −$1.73B | −$1.46B | −$1.38B |
| Graham net-net per share | $1.27 | −$10.56 | −$9.31 | −$7.68 | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $17.7M | $8.8M | $3.3M | — | — | — |
| Share buybacks (net) | $113,000 | $0 | $0 | — | $7.9M | $34.1M | $40.9M | — | $9.2M | $13.0M |
| Dividend payout ratio | — | — | — | — | 63.8% | 28.5% | 4.1% | — | — | — |
| Dividends + buybacks / free cash flow | 0.2% | — | — | — | 44.6% | — | — | — | — | — |
| Capex / revenue | 2.0% | 2.0% | 7.3% | 16.3% | 74.6% | 76.6% | 188.1% | 144.1% | 85.4% | 156.0% |
| Capex / operating cash flow | 19.6% | — | — | — | 79.2% | 125.6% | 452.2% | 323.6% | 194.4% | 264.2% |
| Capex / depreciation | 0.72 | 0.17 | 0.46 | 0.88 | 1.98 | 2.80 | 6.58 | 4.43 | 2.36 | 3.41 |
| Stock-based compensation / revenue | 8.6% | 4.5% | 5.0% | 8.9% | 0.6% | 0.7% | 0.7% | 0.6% | 0.6% | 0.8% |
| R&D / revenue | 5.6% | 27.6% | 38.2% | 39.2% | — | — | — | — | — | — |
| SG&A / revenue | 48.3% | 78.1% | 95.2% | 113.9% | 9.3% | 12.7% | 11.6% | 12.3% | 12.1% | 11.1% |
| Efficiency | ||||||||||
| Days sales outstanding | 45.0 | 63.5 | 56.9 | 130.3 | 188.7 | 145.3 | 115.1 | 96.6 | 99.3 | 111.6 |
| Days of inventory on hand | 69.0 | 69.2 | 80.8 | 96.0 | — | — | — | — | — | — |
| Days payables outstanding | 44.8 | 42.6 | 45.4 | 31.6 | 18.2 | 12.4 | 12.7 | 22.0 | 30.0 | 30.0 |
| Cash conversion cycle (days) | 69.2 | 90.2 | 92.3 | 194.7 | 170.5 | 132.9 | 102.4 | 74.5 | 69.3 | 81.5 |
| Receivables turnover | 8.10 | 5.74 | 6.41 | 2.80 | 1.93 | 2.51 | 3.17 | 3.78 | 3.68 | 3.27 |
| Payables turnover | 8.15 | 8.57 | 8.04 | 11.54 | 20.05 | 29.47 | 28.74 | 16.56 | 12.18 | 12.15 |
| Inventory turnover | 5.29 | 5.27 | 4.52 | 3.80 | — | — | — | — | — | — |
| Asset turnover | 1.11 | 1.09 | 0.54 | 0.16 | 0.11 | 0.14 | 0.16 | 0.16 | 0.15 | 0.13 |
| Average receivables | $100.2M | $71.8M | $47.8M | $92.3M | $152.0M | $165.8M | $136.3M | $92.2M | $80.1M | $76.3M |
| Average payables | $33.5M | $27.2M | $27.0M | $15.5M | $5.5M | $7.3M | $7.6M | $10.8M | $12.9M | $10.2M |
| Average inventory | $51.6M | $44.3M | $48.0M | $47.0M | — | — | — | — | — | — |
| Intangibles / total assets | 1.7% | 5.6% | 4.7% | 2.7% | 0.0% | 0.7% | 0.7% | 1.0% | 1.2% | 0.2% |
Computed from CAI's annual financial statements (latest annual report filed March 3, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CAI valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 18.1 and the forward P/E is 43.3. It ended the year with $379.0 million of debt and $800.1 million in cash and short-term investments, a net cash position of $421.1 million. It returned $0.1 million to shareholders: $0 in dividends and $0.1 million in share buybacks, 0% of free cash flow.
See the CAI income statement, the CAI chart for price history, or the CAI stock overview for the latest quote and news.
CAI key metrics FAQ
What is Caris Life Sciences's P/E ratio?
Caris Life Sciences's trailing P/E ratio is 18.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 43.3. At the end of fiscal 2025 it was —.
What is Caris Life Sciences's EV/EBITDA?
Caris Life Sciences's enterprise value was 650.3 times EBITDA at the end of fiscal 2025 (enterprise value $7.4 billion, EBITDA $11.4 million); the current EV/EBITDA is 49.8.
How much debt does Caris Life Sciences have?
Caris Life Sciences had total debt of $379.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.66 and more cash than debt.
Does Caris Life Sciences buy back its shares?
Yes. Caris Life Sciences spent $0.1 million on net share repurchases in fiscal 2025 Shares outstanding changed +13.8% over the year, to 289.9M..
What is Caris Life Sciences's free cash flow yield?
Caris Life Sciences generated $66.9 million of free cash flow in fiscal 2025, a free cash flow yield of 0.9% on its market value at year-end ($7.8 billion).
What is Caris Life Sciences's current ratio?
Caris Life Sciences's current ratio was 7.85 at the end of fiscal 2025: current assets were 7.85 times current liabilities.